SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

DelveInsight's 'Exosomes Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and ...

Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, ...

Kymera Therapeutics is pivoting focus from oncology to immunology, with plans to only develop cancer programs beyond phase 1 studies via partnerships. | Kymera Therapeutics is pivoting its focus from ...

Paper highlights Zabalafin Hydrogel's potential as a single topical atopic dermatitis therapy that impacts the Staphylococc ...

Collaboration Revenues: Collaboration revenues were $3.7 million for the third quarter of 2024, compared to $4.7 million for the same period of 2023. Collaboration revenues in the third quarter of ...

Explore innovative nutritional and microbial strategies for effectively treating acne, alopecia, and atopic dermatitis.

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could ...

Alopecia areata and asthma are strongly linked, particularly through the inflammatory protein IL-33, suggesting a shared biological pathway and potential for targeted treatments like dupilumab.

In this article, we take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused ...

The third edition of ImmunoSkin underscored Almirall’s commitment to advancing the scientific understanding of skin and its diseases, and to pioneering innovation in medical dermatology and ...